Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Prices IPO

NEW YORK (GenomeWeb News) – Cellular Dynamics International has priced its initial public offering at $12 per share, the stem cell technology firm announced late Wednesday.

Its shares are anticipated to trade on the Nasdaq under ticker symbol "ICEL." CDI is offering about 3.8 million shares in its IPO. Additionally it granted its underwriters a 30-day option to purchase an additional 576,900 shares.

JP Morgan Securities is the sole book-running manager on the offering. Cowen &Co and Leerking Swann are co-managers.

Proceeds will go toward R&D, sales and marketing, expansion of its sales force for commercialization of its products, building out of its laboratory, and working capital general corporate purposes.

CDI filed for its IPO last month.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.